Search
Lisuride
go.drugbank.com/drugs/DB00589ApprovedIt may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists). … An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigationalBedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. … [A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSX-682
go.drugbank.com/drugs/DB19210Investigationalclinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma … Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalEfinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigational) or Sézary syndrome (SS) after at least one prior systemic therapy. … Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR). … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMethyclothiazide
go.drugbank.com/drugs/DB00232ApprovedWithdrawnA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Droxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.